Kab mob qog ntshav Lymphoblastic loj heev (T-ALL)-09

Ib tug tub ntxhais kawm ntawv qib siab hu ua Mengmeng los ntawm Yanjiao, Guizhou, tau txais kev kho mob zoo ntawm BIOOCUS Medical Group.

Mengmeng, poj niam, muaj 21 xyoo, tau tuaj rau peb lub tsev kho mob sab nraud thaum Lub Rau Hli 22, 2021, nrog kev qaug zog tas li. Kev kuaj ntshav qhia tau tias WBC 479 × 10 ^ 9 / L. Kev kuaj pob txha ntxiv tau lees paub tias muaj mob leukemia lymphoblastic (T-cell subtype). Nws tau txais kev kho mob chemotherapy ob zaug, tab sis leukemia tseem tsis teb, nrog MRD (kab mob tsawg kawg nkaus) ntawm 56.01%, thiab nws kuj muaj kev koom tes hauv kev mob leukemia ntawm lub paj hlwb.

Thaum Lub Yim Hli 13, cov lymphocytes autologous tau raug sau thiab muab tshuaj chemotherapy. Thaum Lub Yim Hli 30, Mengmeng tau txais CD7 CAR-T cell infusion. Ob lub lis piam tom qab infusion, kev kuaj pob txha qhia tau tias nws zoo tag nrho, MRD tsis zoo, thiab tswj tau tus kab mob leukemia hauv lub paj hlwb. Nws tau muaj tus kab mob cytokine release syndrome (CRS) qib 1 uas tsis muaj kev phiv tshuaj hauv lub paj hlwb.